Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Akkermansia Probiotics
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colo-rectal Cancer
1 trial -
Albumin paclitaxel/neutrophil drug
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Albumin-Bound Paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Carcinoma
1 trial -
Albuterol
The First People's Hospital of Lianyungang
Chronic Obstructive Pulmonary Disease
1 trial -
Amberen
The First People's Hospital of Lianyungang
Climacteric Syndrome
1 trial -
Ambrisentan
The First People's Hospital of Lianyungang
Pulmonary Arterial Hypertension
1 trial -
Amino acid-derived lipids
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation Dermatitis
1 trial -
Amivita
Wujin People's Hospital
Amyotrophic Lateral Sclerosis
1 trial -
Amway Herbal Drink
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Skin Laxity
1 trial -
Andrositol Plus
Hospital Authority, Hong Kong
Male Infertility
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Autoimmune Diseases
1 trial -
Anti-HER2 CAR-T cells
The First People's Hospital of Lianyungang
HER2-positive Advanced Malignant Solid Tumors
1 trial -
Anti-PD1
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma (NPC)
1 trial -
Anti-infective therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Bronchiectasis Adult
1 trial -
AntiPlatelet therapy
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
Antibiotic selection based on the antibiotic susceptibility testing
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastritis
1 trial -
Arbidol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Allergic Rhinitis
1 trial -
Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
The First People's Hospital of Lianyungang
Ovarian Cancer
1 trial -
Artificial intelligence
Hospital Authority, Hong Kong
Internal Disease
1 trial -
Artificial intelligence-assisted chest X-ray in TB screening
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tuberculosis (TB)
1 trial -
Aspirin
The First People's Hospital of Lianyungang
Anterior Ischemic Optic Neuropathy
1 trial -
Atorvastatin
The First People's Hospital of Lianyungang
Contrast-induced Acute Kidney Injury
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources